Biotransformation of geldanamycin and 17-allylamino-17- demethoxygeldanamycin by human liver microsomes: Reductive versus oxidative metabolism and implications

Drug Metabolism and Disposition

Volumn 35, Issue 1, 2007, Pages 21-29

  Lang, Wensheng ^a   Caldwell, Gary W ^a   Li, Jian ^a   Leo, Gregory C ^a   Jones, William J ^a   Masucci, John A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 O DEMETHYL 17 (2',3' DIHYDROXYPROPYLAMINO) GELDANAMYCIN; 12 O DEMETHYL 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN HYDROQUINONE; 17 (2',3' DIHYDROXYPROPYLAMINO) GELDANAMYCIN; 17 (3' HYDROXYALLYLAMINO) GELDANAMYCIN; 17 (DIDEHYDROALLYLAMINO) GELDANAMYCIN; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN HYDROQUINONE; 17 AMINOGELDANAMYCIN; 17 O DEMETHYLGELDANAMYCIN; 19 GLUTATHIONYL GELDANAMYCIN HYDROQUINONE; 22 HYDROXYL 17 (2'.3' DIHYDROPROPYLAMINO) GELDANAMYCIN; 22 HYDROXYL 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN HYDROQUINONE; 6 O DEMETHYL 17 (2',3' DIHYDROXYPROPYLAMINO) GELDANAMYCIN; ANSAMYCIN DERIVATIVE; CYTOCHROME P450 REDUCTASE; DRUG METABOLITE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYDROQUINONE; HYDROQUINONE DERIVATIVE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; BIOTRANSFORMATION; DRUG CONJUGATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYPOXIA; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN INTERACTION;

ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; BIOTRANSFORMATION; CELL HYPOXIA; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICROSOMES, LIVER; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION;

EID: 33845956606     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.009639     Document Type: Article

References (33)

1. erbB2, Raf-1 and mutant p53 proteins by gledanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 40:60-64.
2. Bachur NR, Gordon SL, and Gee MV (1978) A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38:1745-1750.
3. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, et al. (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxy-geldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152-4161.
4. Basso AD, Solit DB, Munster PN, and Rosen N (2000) Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159-1166.
5. Benchekroun MN, Myers CE, and Sinha BK (1994) Free radical formation by ansamycin benzoquinone in human breast tumor cells: implications for cytotoxicity and resistance. Free Radic Biol Med 17:191-200.
6. Billecke SS, Bender AT, Kanelakis KC, Murphy PJM, Lowe ER, Kamada Y, Pratt WB, and Osawa Y (2002) Hsp90 is required for heme binding and activation of apo-neuronal nitric-oxide synthase: geldanamycin-mediated oxidant generation is unrelated to any action of hsp90. J Biol Chem 277:20504-20509.
7. erbB2. J Biol Chem 271:4974-4977.
8. Cysyk RL, Parker RJ, Barchi JJ, Steeg PS, Hartman NR, and Strong JM (2006) Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem Res Toxicol 19:376-381.
9. Dikalov S, Landmesser U, and Harrison DG (2002) Geldanamycin leads to superoxide formation by enzymatic and non-enzymatic redox cycling: implications for studies of HSP90 and endothelial cell nitric-oxide synthase. J Biol Chem 277:25480-25485.
10. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, and Eiseman JL (1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58:2385-2396.
11. 1 mice and Fisher 344rats. Proc Am Assoc Cancer Res 38:308.
12. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, and Ross D (2005) Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65:10006-10015.
13. Hansch C, Leo A, and Taft RW (1991) A survey of Hammett substituent constants and resonance and field parameters. Chem Rev 91:165-195.
14. Jorgensen WL, Maxwell DS, and Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energies and properties of organic liquids. J Am Chem Soc 118:11225-11236.
15. Kalyanaraman B, Perez-Reyes E, and Mason RP (1980) Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochim Biophys Acta 630:119-130.
16. Lang W, Caldwell GW, and Masucci JA (2005) Evaluation of the effect of oxygen exposure on human liver microsomal metabolism of mitomycin C in the presence of glutathione using liquid chromatography-quadrupole time of fight mass spectrometry. Anal Biochem 343:268-276.
17. Lang W, Mao J, Doyle TW, and Almassian B (2000a) Isolation and identification of urinary metabolites of porfiromycin in dogs and humans. Drug Metab Dispos 28:899-904.
18. Lang W, Mao J, Wang Q, Niu C, Doyle TW, and Almassian B (2000b) Isolation and identification of metabolites of porfiromycin formed in a rat liver preparation. J Pharm Sci 89:191-198.
19. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, and Zhong H (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478-2482.
20. Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, and Moyer JD (1994) Depletion of the erbB-2 gene product p185 by benzoquinonoid ansamycins. Cancer Res 54:2724-2730.
21. Munro AW, Noble MA, Robledo L, Daff SN, and Chapman SK (2001) Determination of the redox properties of human NADPH-cytochrome P450 reductase. Biochemistry 40:1956-1963.
22. Musser SM, Egorin MJ, Zuhowski EG, Hamburger DR, Parise RA, Covey JM, White KD, and Eiseman JL (2003) Biliary excretion of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats. Cancer Chemother Pharmacol 52:139-146.
23. Qui D, Shenkin PS, Hollinger FP, and Still CW (1997) The GB/SA continuum model for salvation. A first analytic method for the calculation of approximate Born radii. J Phys Chem A 101:3005-3014.
24. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, et al. (2005) Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11:3385-3391.
25. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Mumi ML, DiOrio CI, Barbacci EG, Miller PE, et al. (1995a) erbB-2 Oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 38:3813-3820.
26. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, et al. (1995b) Geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 38:3806-3812.
27. Schulte TW and Neckers LM (1998) The benzoquinone ansamycin 17-allyamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42:273-279.
28. Shen G and Blagg BS (2005) Radester, a novel inhibitor of the Hsp90 protein folding machinery. Org Lett 7:2157-2160.
29. Stancato LF, Silverstein AM, Owens-Grillo JK, Chow Y, Jove R, and Pratt WB (1997) The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem 272:4013-4020.
30. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, and Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239-250.
31. Supko JG, Hickman RL, Grever MR, and Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-315.
32. Wardman P (1990) Bioreductive activation of quinones: redox properties and thiol reactivity. Free Radic Res Commun 8:219-229.
33. v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91:8324-8328.